Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $372.7 million.

  • Cartesian Therapeutics' Liabilities and Shareholders Equity fell 1815.03% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 1202.88%. This contributed to the annual value of $435.0 million for FY2024, which is 4260.71% up from last year.
  • Cartesian Therapeutics' Liabilities and Shareholders Equity amounted to $372.7 million in Q3 2025, which was down 1815.03% from $388.9 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $455.3 million for Q3 2024, and its period low was $106.0 million during Q3 2023.
  • Its 5-year average for Liabilities and Shareholders Equity is $252.8 million, with a median of $180.5 million in 2021.
  • Per our database at Business Quant, Cartesian Therapeutics' Liabilities and Shareholders Equity crashed by 4051.89% in 2023 and then surged by 32940.57% in 2024.
  • Cartesian Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $159.9 million in 2021, then rose by 3.75% to $165.9 million in 2022, then surged by 83.89% to $305.0 million in 2023, then skyrocketed by 42.61% to $435.0 million in 2024, then decreased by 14.33% to $372.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $372.7 million for Q3 2025, versus $388.9 million for Q2 2025 and $409.1 million for Q1 2025.